Following Q4 results, updated 2018 tax and EPS guidance, Leerink analyst Seamus Fernandez tells investors that the pressure in Eli Lilly's shares was "surprising." The analyst views the move as an "overreaction" by investors, but acknowledges that 2018 poses some legitimate risks for diabetes and animal health franchises which we highlighted in an earlier note. It its "hard to get excited" given competitive headwinds, but valuation downside is limited, he contends. Fernandez reiterates a Market Perform rating on the stock, while raised his price target on the shares to $98 from $95 due to the benefit of tax.